pipeline ESTEVE

Our R&D portfolio currently consists of:

- New Chemical Entities in various fields, such as neurology and analgesia.

- New Advanced Therapies for inherited metabolic disorders.

Our portfolio and continued commitment to R&D, together with our manufacturing capacity, have allowed us to receive an "Excellent" rating in Group A of the Spain's Profarma Plan (Plan to Promote Scientific Research, Technological Development and Innovation in the Pharmaceutical Industry) continuously since 1986.

ESTEVE is implementing various programs that are currently in diverse stages of research and development.

Small Molecule Gene therapy

Moderate-to-Severe Acute Pain

E-58425: a novel, first-in-class co-crystal of Celecoxib and Tramadol

July 2019 update: United States Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for E-58425.

Neuropathic Pain

E-52862: a novel, first-in-class NCE selective Sigma-1 antagonist

Mucopolysaccharidosis Type IIIA

EGT-101: a potential first-in-class AAV-9 gene therapy administered via a one-time intracerebroventricular injection into the cerebrospinal fluid

General information about Sanfilippo Syndrome Type A or mucopolysaccharidosis (MPS) IIIA.    See more

Pain-Related Disorders (Undisclosed)

MUMO-1: a novel, first-in-class NCE with a multi-modal mechanism of action that includes Sigma-1 antagonism

Mucopolysaccharidosis Type IIIB

EGT-201: a potential first-in-class AAV-9 gene therapy

Mucopolysaccharidosis Type II

EGT-301: a potential first-in-class AAV-9 gene therapy


MUMO-5: a novel, first-in-class NCE with multimodal mechanisms of action

Lysosomal Storage Disorder (Undisclosed)

A potential first-in-class gene therapy

Neurodegenerative Disorders (Undisclosed)

Unique Sigma-1 Platform of agonists and antagonists